The goals of this study were to evaluate the effects of suvecaltamide on BTZ-induced CIPN and to determine whether suvecaltamide interferes with BTZ anti-cancer activity (proteasome inhibition, cytotoxicity, and anti-tumor activity) in rodent models and human multiple myeloma cell lines (MCLs). The gene discussed is CASC3; the disease is AL amyloidosis.